Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818892 · ClinicalTrials.gov registry record
Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 222
- Enrollment target
NCT04818892 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 222 participants.
The verdict
NCT04818892 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 222 participants
- Enrollment target
Study Summary
The overall objective of this proposal is to evaluate the safety and immunogenicity of a COVID-19 vaccine in patients with Inflammatory Bowel Disease (IBD). This will help determine if immunosuppressive regimens impact COVID-19 vaccine response. The investigators will determine if certain groups may need more doses of a vaccine, with future adjuvanted vaccines or require a booster to maintain immunity. 260 participants with IBD and scheduled to get a COVID-19 vaccine will be recruited and can expect to be on study for 18 months.
Interventions
- DIAGNOSTIC_TEST Serological Assay for SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2022-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818892
The ClinicalTrials.gov registry entry for NCT04818892 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Serological Assay for SARS-CoV-2 is the first listed.
NCT04818892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04818892 about?
NCT04818892 is a clinical study titled "Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease". The overall objective of this proposal is to evaluate the safety and immunogenicity of a COVID-19 vaccine in patients with Inflammatory Bowel Disease (IBD). This will help determine if immunosuppressive regimens impact COVID-19 vaccine response. The investigators will determine if certain groups may...
What is the current status of trial NCT04818892?
This trial is currently completed. The enrollment target is 222 participants. The study started on 2021-03-26. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT04818892?
The interventions under investigation include: Serological Assay for SARS-CoV-2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04818892?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.